ArticleJournal of Korean medical science2026
Resurgence of Human Adenovirus Infections in the Korean Military Following the COVID-19 Pandemic.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe study investigates the epidemiological and clinical characteristics of the resurgence of human adenovirus (HAdV) infections among Korean military personnel following the easing of the coronavirus disease 2019 restrictions, with a focus on serotype distribution and healthcare utilization.
methodsWe conducted a retrospective descriptive study of 450 laboratory-confirmed HAdV cases identified between January 2023 and July 2024. We retrieved data from the New Defense Medical Information System and performed serotyping on a subset of samples using real-time polymerase chain reaction and sequencing.
resultsHAdV cases increased sharply beginning in late 2023 and peaked in July 2024. Serotyping revealed a significant shift: HAdV-14 accounted for 98.8% of typed cases, replacing the historically dominant HAdV-55. Most patients presented with respiratory symptoms, although gastrointestinal symptoms were also common. Co-infections occurred in 7.3% of cases. 26.2% of patients required hospitalization, with a mean stay of 7.4 days. One patient required intensive care.
conclusionThis study highlights the resurgence and serotype shift of HAdV infections in a military population, reflecting post-pandemic viral dynamics. The findings underscore the need for continuous molecular surveillance and strengthened preparedness strategies in congregate military settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.